ACYP1抗体

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Human fetal brain tissue lysate, Primary antibody: P07769(ACYP1 Antibody) at dilution 1/700, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P07769(ACYP1 Antibody) at dilution 1/65. (Original magnification: ×200)    

  
  

ACYP1 (acylphosphatase 1) is an enzyme encoded by the *ACYP1* gene, belonging to the acylphosphatase family, which hydrolyzes acyl phosphates to carboxylates and inorganic phosphate. This enzyme is implicated in cellular metabolism, particularly in energy-related processes and ion transport regulation. ACYP1 is expressed in various tissues, with higher levels observed in skeletal muscle, erythrocytes, and the brain. Its biological role remains under investigation, though studies suggest potential involvement in modulating calcium signaling, ATP metabolism, and cellular stress responses. Dysregulation of ACYP1 has been explored in pathological contexts, including neurodegenerative disorders and cancer. For instance, altered ACYP1 expression has been linked to Alzheimer’s disease, where it may influence amyloid-beta metabolism, and in certain cancers, where it could serve as a biomarker for tumor progression or drug resistance.

ACYP1 antibodies are essential tools for studying the protein’s expression, localization, and function. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect ACYP1 in biological samples. Commercial ACYP1 antibodies are typically raised in rabbits or mice using peptide antigens derived from the human ACYP1 sequence. Validation includes specificity tests (e.g., siRNA knockdown or knockout controls) and application-specific performance checks. Researchers employ these antibodies to explore ACYP1’s role in diseases, such as its interaction with neurodegenerative pathways or oncogenic mechanisms. However, variability in antibody performance (e.g., cross-reactivity) necessitates careful optimization for experimental accuracy. Ongoing research aims to clarify ACYP1’s precise molecular mechanisms and therapeutic potential, driving demand for reliable antibodies in both basic and translational studies.